DNA Methylation in Patients with Non-Hodgkin's Lymphoma

非霍奇金淋巴瘤患者的 DNA 甲基化

基本信息

批准号：
6548453
负责人：
VICTOR V LEVENSON
金额：
$ 14.9万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2002
资助国家：
美国
起止时间：
2002-09-01 至 2004-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/6548453
关键词：
B cell lymphoma DNA methylation SDS polyacrylamide gel electrophoresis cell line clinical research diagnosis design /evaluation diagnosis quality /standard fluorescent dye /probe gene expression high throughput technology human genetic material tag human tissue microarray technology neoplasm /cancer diagnosis neoplasm /cancer genetics neoplastic process polymerase chain reaction tissue /cell culture

项目摘要

Technological advances of molecular biology are posed to bring new methods of diagnosis and treatment to clinical practice. Among other things these methods should improve on the sensitivity of existing techniques, be sufficiently robust to allow multi-parametric evaluation of clinical samples, and should not require invasive procedures for sample acquisition. In this proposal we will test a combination of existing modern techniques, which is designed to provide high-throughput, multi- parametric detection of diffuse large B-cell lymphoma. In R21 phase of the project we will use cultured cell and paraffin-embedded tissues of patients to determine sensitivity, selectivity and variability of the assay. When the milestones of R21 phase are met we will move into clinical R33 phase of the project, testing the assay's ability to detect lymphoma- specific DNA in patient's plasma. We will test correlation of the assay's results with clinical diagnosis of diffuse large B-cell lymphoma, and with clinical outcomes, including disease-free survival and drug resistence. When the assay is optimized for disease detection in patient's plasma we will also address the issue of residual disease detection and monitoring of treatment efficacy.

分子生物学的技术进步将为临床实践带来新的诊断和治疗方法。除其他外，这些方法应提高现有技术的灵敏度，足够稳健以允许对临床样本进行多参数评估，并且不应需要侵入性程序来采集样本。在本提案中，我们将测试现有现代技术的组合，该技术旨在提供弥漫性大 B 细胞淋巴瘤的高通量、多参数检测。在该项目的 R21 阶段，我们将使用患者的培养细胞和石蜡包埋组织来确定检测的灵敏度、选择性和变异性。当达到 R21 阶段的里程碑后，我们将进入该项目的临床 R33 阶段，测试该检测方法检测患者血浆中淋巴瘤特异性 DNA 的能力。我们将测试检测结果与弥漫性大 B 细胞淋巴瘤的临床诊断以及临床结果（包括无病生存率和耐药性）的相关性。当该检测方法针对患者血浆中的疾病检测进行优化时，我们还将解决残留疾病检测和治疗效果监测的问题。